Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Still a Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw strong trading volume on Thursday . 410,384 shares were traded during trading, an increase of 77% from the previous session’s volume of 231,787 shares.The stock last traded at $23.15 and had previously closed at $23.28.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

Chugai Pharmaceutical Price Performance

The business has a 50-day simple moving average of $25.61 and a 200 day simple moving average of $27.18. The firm has a market cap of $76.79 billion, a PE ratio of 25.92 and a beta of 0.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. The business had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%. On average, equities analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.